Eye Research Foundation Report issue

Academic/Hospital Phase 2 Phase 3
Founded: CA United States (1998)

Organization Overview

First Clinical Trial
2019
NCT04149899
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Eye Research Foundation | Eye Research Foundation, Inc.

Active Ingredients

Drugs in Phase 3 Trials (1)

lotilaner (xdemvy) (1 trial)

Drugs in Phase 2 Trials (3)

jv-gl1 (1 trial)

latanoprost (xalatan) (1 trial)

timolol (blocadren) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Blepharitis (Phase 3)

Glaucoma (Phase 2)

Glaucoma, Open-Angle (Phase 2)

Hypertension (Phase 2)

Ocular Hypertension (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 4